Distinct spatial approximations between residues within the secretin pharmacophore and its receptor can provide important constraints for modeling this agonist-receptor complex. We previously used a series of probes incorporating photolabile residues into positions 6, 12, 13, 14, 18, 22, and 26 of the 27-residue peptide and demonstrated that each covalently labeled a site within the receptor amino terminus. Although supporting a critical role of this domain for ligand binding, it does not explain the molecular mechanism of receptor activation. Here, we developed probes having photolabile residues at the amino terminus of secretin to explore possible approximations with a different receptor domain. The first probe incorporated a photolabile pbenzoyl-L-phenylalanine into the position of ]secretin-27). Each analog was shown to be a full agonist, stimulating cAMP accumulation in receptorbearing Chinese hamster ovary-SecR cells in a concentration-dependent manner, with the position ؊2 probe being most potent. They bound specifically and saturably, although the position 1 analog had lowest affinity, and all were able to label the receptor efficiently. Sequential specific cleavage, purification, and sequencing demonstrated that the sites of covalent attachment for each probe were high within the sixth transmembrane segment. This suggests that secretin binding may exert tension between the receptor amino terminus and the transmembrane domain to elicit a conformational change effecting receptor activation.
The secretin receptor is prototypic of the Class B family of guanine nucleotide-binding protein (G protein)-coupled receptors which includes many important drug targets. Understanding of the molecular basis of ligand binding of receptors is important for the rational design of receptor-active drugs. However, the molecular basis of ligand binding of Class B receptors is less well understood than that of members of the Class A family, such as rhodopsin and the adrenergic receptor. This likely reflects the facts that natural ligands for Class B G protein-coupled receptors are relatively large peptides with diffuse phamacophoric domains and that these receptors have long and complex amino-terminal domains that are important for binding. Both of these interacting domains are flexible, with active conformations that have not been clearly defined.
One of the distinct characteristics of the Class B receptor family is the long amino terminus that exceeds 120 residues in length. It contains 6 conserved Cys residues that have been demonstrated to form intradomain disulfide bonds (1) (2) (3) (4) (5) and to be critical for ligand binding. These disulfide bonds could provide key constraints for building a model of the secretin receptor, but definitive mapping of these bonds in an active receptor has not yet been achieved. A bonding pattern has been proposed for three other Class B G protein-coupled receptors, binding parathyroid hormone (PTH) 1 (3), glucagon-like peptide (4), and corticotropin-releasing factor (2) , based on analysis of the refolded nonglycosylated amino-terminal peptides of these receptors that had been produced in Escherichia coli. It should be noted that the pattern of disulfide bonds obtained from the refolded amino-terminal extracellular domain of the corticotropin-releasing factor is different from that predicted by mutagenesis of that entire receptor (1) . Like that of other members of the Class B family, the complex amino terminus of the secretin receptor has been demonstrated to play a critical role in ligand binding by mutagenesis and chimeric receptor analysis (6, 7) .
We have taken a more direct approach to understanding the molecular basis of secretin binding to its receptor, utilizing intrinsic photoaffinity labeling. This approach can provide information regarding spatial approximations between photolabile residues situated within a ligand and residues adjacent to these when docked at the receptor. We have used a series of probes with a photolabile residue (p-benzoyl-L-phenylalanine (Bpa) or p-benzoylbenzoyl-L-lysine (BzBz)Lys)) in different regions of the peptide, in positions 6, 12, 13, 14, 18, 22, and 26 (8 -13) . Interestingly, all of these probes have been demonstrated to label residues within the amino-terminal domain of the secretin receptor, with six probes labeling the first 40 residues of the amino terminus (8 -11, 13 ) and one labeling a 1 The abbrevations used are: PTH, parathyroid hormone; Bpa, p-benzoyl-L-phenylalanine; Bpa 1 probe, rat lsqb]Bpa residue close to the first transmembrane segment (12) . This strongly supports a critical role for the amino terminus of the secretin receptor in ligand binding.
However, mutagenesis data have shown that, in addition to the amino-terminal region of the secretin receptor, the extracellular loop regions play complementary roles that affect ligand binding. It is not known whether such effects are direct, interacting with the ligand, or indirect, interacting with other portions of the receptor itself. Because the distal amino-terminal region of secretin has been shown to be functionally important and has not yet been studied directly by photoaffinity labeling, in the current work we focused on this region as a possible site of interaction with the body of the receptor. The amino terminus of PTH, the natural ligand of another Class B G protein-coupled receptor, has been shown to interact with the top of the sixth transmembrane segment (TM6) of that receptor (14, 15) . However, incorporation of a photolabile residue at the amino terminus of secretin may be challenging because of the critical importance of His 1 in structure-activity studies (16 In this work, we have successfully synthesized three photolabile analogs and have shown that they are full agonists that bind to the secretin receptor specifically and saturably and that they are able to label this receptor efficiently. All three probes consistently labeled receptor residues in a distinct region that included the top of the secretin receptor TM6. Together with other photoaffinity labeling data we reported previously, these constraints were built into a three-dimensional model of the agonist-bound secretin receptor. These findings add important constraints to the docking of secretin to its receptor and may suggest a mechanism for ligand binding and activation which may be shared by other members of the Class B family of G protein-coupled receptors.
EXPERIMENTAL METHODS
Materials-Cyanogen bromide (CNBr), solid phase oxidant, N-chloro-benzenesulfonamide (IODO-BEADS), m-maleimidobenzoyl-Nhydroxysulfosuccinimide ester (Sulfo-MBS), and acetic anhydride were purchased from Pierce. Endoproteinase Lys-C was from Calbiochem. 3-Isobutyl-1-methylxanthine and N-(2-aminoethyl-1)-3-aminopropyl glass beads were from Sigma. Endoglycosidase F was produced in our laboratory (17) . All other reagents were analytical grade.
Peptides , were designed to contain a Tyr residue at position 10 for radioiodination and a photolabile residue, Bpa, in positions near the amino terminus, for covalent labeling of the secretin receptor. These three probes and other peptides used in this study, i.e. rat secretin-27 and the peptide used for radiolabeling, rat [Tyr 10 ]secretin-27, were synthesized by manual solid phase techniques and purified to homogeneity by reversed-phase HPLC, as described previously (18) . Their chemical identities were established by mass spectrometry. The above three photolabile probes and the radioligand used in receptor binding studies were radioiodinated oxidatively with Na 125 I upon exposure to an IODO-BEAD for 15 s and purified by reversed-phase HPLC to yield specific radioactivities of 2,000 Ci/mmol (18) .
Receptor Preparations-Secretin receptor-bearing Chinese hamster ovary cell line (CHO-SecR), which has been previously established and characterized (19) , was used as source of wild type receptors for the current study. In this work, it was necessary to develop new secretin receptor mutants that incorporated additional sites for CNBr cleavage in the first extracellular loop (ECL1) and TM6. Ile (I334M/M344I ). These mutants were prepared using an oligonucleotide-directed approach with the QuikChange TM site-directed mutagenesis kit from Stratagene, with the products verified by direct DNA sequencing (20) .
A CHO cell line stably expressing the I334M/M344I construct was produced using the same methodology utilized previously (21) . This cell line and the CHO-SecR line were cultured at 37°C in a 5% CO 2 environment on Falcon tissue culture plastic ware in Ham's F-12 medium supplemented with 5% fetal clone-2 (Hyclone Laboratories, Logan, UT). Cells were passaged twice a week and lifted mechanically before use. The A175M, L324M, I331M, I334M, and I331M/M344I mutant receptor constructs were expressed transiently on COS cells (American Type Cell Collection, Manassas, VA) after transfection using a modification of the DEAE-dextran method (7) . These cells were harvested mechanically 72 h after transfection. Receptor-enriched plasma membranes were prepared from these cell lines using methods that we reported previously (21) .
Biological Activity Assay-The agonist activities of the Bpa 1 , Bpa Ϫ1 , and Bpa Ϫ2 probes were studied for stimulation of cAMP activity in the CHO-SecR cells using a competitive binding assay (Diagnostic Products Corporation, Los Angeles, CA). Cells were stimulated with the secretin analogs at 37°C for 30 min, and the reaction was stopped by adding ice-cold perchloric acid. After adjusting the pH to 6 with KHCO 3 , cell lysates were cleared by centrifugation at 3,000 rpm for 10 min, and the supernatants were used in the assay, as described previously (22) . Radioactivity was quantified by scintillation counting in a Beckman LS6000. This assay was also used to characterize functionally the new receptor mutants expressed transiently in COS cells.
Ligand Binding-Binding to the secretin receptor was characterized in a standard assay using membranes from the CHO-SecR cell line as source of receptor. Membranes (5 g ]-secretin-27 in the absence of competing secretin. After photolysis, membranes were washed, pelleted, solubilized in SDS sample buffer, and applied to a 10% SDS-polyacrylamide gel for electrophoresis (23) . Radiolabeled bands were detected by autoradiography.
Identification of the Labeled Receptor Domains-Radioactive receptor bands were cut out from the gel and homogenized in water in a Dounce homogenizer, followed by elution, lyophilization, and ethanol precipitation. This material was used for chemical or enzymatic cleavage experiments. Aliquots of affinity labeled secretin receptor were deglycosylated with endoglycosidase F, as described previously (21) .
CNBr and endoproteinase Lys-C were used separately or in sequence to cleave the labeled secretin receptor or its mutants using procedures described previously (8) . The products of cleavage were resolved on 10% NuPAGE gels using MES running buffer (Invitrogen). After electrophoresis, labeled bands were identified by exposure to x-ray film with intensifying screens at Ϫ80°C.
In addition to peptide mapping by chemical and enzymatic cleavage, as described above, identification of the secretin receptor fragments affinity-labeled with the Bpa Ϫ1 and Bpa Ϫ2 probes was also achieved by Edman degradation sequencing of the purified CNBr fragments of the labeled receptor. For this, plasma membranes (10 mg) were photoaffinity labeled with 0. ] secretin-27 and were gel purified by the procedure described above. Labeled receptors were cleaved by CNBr and the resulting fragments were purified by gel electrophoresis followed by elution, lyophilization, and acetone precipitation. Purified fragments were then injected onto a PerkinElmer Life Sciences/Brownlee microbore C-18 HPLC column, utilizing a flow rate of 5 l/min and 10 min of 1% solution B, followed by a linear gradient up to 80% solution B over 190 min (A, 0.1% trifluoroacetic acid, and B, 0.085% trifluoroacetic acid and acetonitrile). The separation was monitored at 280 nm with a UV absorbance detector. The eluant from this microbore column was collected directly onto a polyvinylidene difluoride membrane strip that was subsequently exposed to x-ray film for detection of the position of the radioactive peak. The peak area was excised from the membrane and subjected to Edman degradation sequencing using an Applied Biosystems automated instrument.
Identification of Labeled Receptor Residues-Considering that the photolabile residue Bpa was located in the first position of the secretin analogs used in this study, caution was required to prevent cleavage of the Bpa in the first cycle of radiochemical Edman degradation sequencing of the attached receptor fragment. This was achieved by acetylation of the free amino group of the photolabile probe using acetic anhydride after photoaffinity labeling of the receptor, but prior to CNBr cleavage. For this, gel-purified and ethanol-precipitated labeled secretin receptor was dissolved in 200 l of 0.1 M phosphate buffer (pH 7.8) containing 0.1% SDS. 20 l of acetic anhydride was added in 5-l aliquots over the course of 1 h, and the reaction was incubated for an additional hour with stirring at room temperature in the dark. Acetylated materials were ethanol precipitated prior to CNBr cleavage. After gel purification, the CNBr fragment was used for Edman degradation to localize the receptor residues labeled by these probes. Radiochemical sequencing was performed on cysteine-containing CNBr fragments of the receptor which were immobilized through sulfhydryl groups using the bifunctional cross-linker, Sulfo-MBS, and N-(2-aminoethyl-1)-3-aminopropyl glass beads. Edman degradation was manually repeated in a manner that has been reported previously in detail (24, 25) , and the radioactivity released in each cycle was quantified in a ␥-spectrometer.
Statistical Analysis-All observations were repeated at least three times in independent experiments and are expressed as the means Ϯ S.E. Binding curves were analyzed and plotted using the nonlinear regression analysis routine for radioligand binding in the Prism software package (GraphPad Software, San Diego). Binding kinetics was determined by analysis with the LIGAND program of Munson and Rodbard (26) .
Molecular Modeling-Homology modeling techniques were employed to model both the receptor amino-terminal region and transmembrane region. The two regions were then connected guided by experimental data reported previously (27) . A detailed description of the receptor modeling has been reported elsewhere (13) . Here we give a brief summary.
For modeling of the amino-terminal region, sequence data bases were searched for homologs of each of the closely related Class B family amino-terminal domains using FASTA3 (28) . Homologs with experimentally determined three-dimensional structures were assessed for suitability as templates in a homology modeling exercise, using structure-based sequence alignment of the secretin receptor amino terminus incorporated in MOE (29) . Three-dimensional homology models for the rat secretin receptor amino terminus were then built using Modeler (30) . Final models were assessed for stereochemical quality and side chain packing profiles using the PROCHECK (31) and QPACK programs (32) . The first eight residues of the amino-terminal region were then built into the homology model as an extended conformation, and the rest of carboxyl-terminal residues (109 -122) were modeled as two ␣-helices approximately perpendicular to each other as suggested by experimental data (27) .
To model the receptor transmembrane domain, the transmembrane helix sequences of the rat secretin receptor were aligned with those of bovine rhodopsin (PDB code: 1F88) based on the previously reported alignment derived using the "cold spot" method (33) . A homology model for the transmembrane domain was built using Sybyl 6.9 (34) . Extracellular and cytosolic loops were built by first defining anchoring residues located at each helix terminus, then searching a data base of protein loops for a proper template to model them. The last carboxylterminal helix of the amino-terminal domain model described above was treated as the beginning of transmembrane helix 1, these fragments were superimposed, and the two domains connected to create an intact secretin receptor model.
The NMR-derived solution structure of secretin (35) was manually docked close to its putative binding site in the three-dimensional model, guided by our previous photoaffinity labeling data (8 -13) . The docked complex model was then subjected to 100 steps of in vacuo energy minimization with no constraints, followed by brief (5 ps), low temperature (40 K) molecular dynamics simulations using a generalized Born model. Six constraints were applied to impose peptide-receptor contacts determined from previous and current photoaffinity labeling experiments during the MD simulation, using a harmonic restraining potential with a 20 kcal/mol/Å force constant. In addition, weak harmonic constraints (2.0 kcal/mol/Å) were applied to maintain transmembrane helix backbone atoms close to their initial positions. The last configuration from the simulation was then energy minimized to generate a final structure for the complex.
All energy minimization and molecular dynamics calculations were carried out with the AMBER 7 program (36) . Interactive molecular graphics model building and analyses were performed using PSSHOW (37) . Molecular views were drawn with the MOLSCRIPT program (38) .
RESULTS
Probe Preparation and Characterization-A goal for this study was to develop secretin probes incorporating a photolabile residue at the amino terminus; however, His 1 of secretin is known to be critical for ligand binding and biological activity (16 ]secretin-27 (Bpa Ϫ2 probe). These were synthesized by manual solid phase techniques, purified, and characterized to demonstrate the expected molecular masses by matrix-assisted laser desorption/ionization-time of flight mass spectrometry.
As shown in Fig. 1 , all three probes bound to the secretin receptor specifically and saturably with the Bpa Ϫ2 probe (K i ϭ 1.1 Ϯ 0.3 nM) having higher affinity than the Bpa Ϫ1 probe (K i ϭ 28 Ϯ 9 nM) and Bpa 1 probe (K i ϭ 71 Ϯ 4 nM). They all were full agonists, stimulating an intracellular cAMP accumulation in CHO-SecR in a concentration-dependent manner (Fig. 1) . Consistent with the binding data, the Bpa Ϫ2 probe (EC 50 ϭ 21 Ϯ 5 pM) was more potent than the Bpa Ϫ1 probe (EC 50 ϭ 187 Ϯ 55 pM) and the Bpa 1 probe (EC 50 ϭ 27 Ϯ 7 nM). All three analogs were used further for exploration of their molecular approximations with this receptor.
Photoaffinity Labeling of the Secretin Receptor-To explore the ability of these probes to label the secretin receptor covalently, all three probes were used in photoaffinity labeling experiments with CHO-SecR plasma membranes in the presence and absence of competing secretin. As shown in Fig.  2 , all three probes efficiently labeled the secretin receptor in a concentration-dependent manner. The receptor labeled with each probe migrated at M r ϭ 70,000, which shifted to M r ϭ 42,000 after deglycosylation with endoglycosidase F. This migration is the same as the secretin receptor labeled with the previously reported probes (8 -13) . Fig. 2 probe, 12 Ϯ 3 nM; Bpa 1 probe, 1.7 Ϯ 0.6 nM). These bands were absent when following the same affinity labeling procedure using nonreceptor bearing CHO membranes (Fig. 2) .
Identification (Fig. 3, highlighted  fragments) .
To define further which fragment was labeled, two secretin receptor constructs, A175M and I334M, were generated to introduce a Met residue into each of the candidate fragments. These two receptor mutants had normal affinity to bind secretin, and both had similar efficacies and potencies to elicit cAMP responses to secretin stimulation as for the wild type receptor (Table I) . Furthermore, these constructs were specifically and saturably labeled by the Bpa Ϫ1 , Bpa Ϫ2 , and Bpa 1 probes, with similar efficiencies to labeling the wild type receptor (Fig. 4) . Both constructs labeled with each probe were then submitted to CNBr cleavage. As shown in Fig. 4 , CNBr cleavage of the I334M mutant labeled with the Bpa Ϫ1 probe yielded a fragment migrating at approximate M r ϭ 7,500 which migrated faster than the fragments resulting from CNBr cleavage of either the labeled wild type or the A175M receptor constructs Receptor-bearing membranes were labeled in the absence or presence of increasing concentrations of competing unlabeled secretin (A). The labeled receptor was deglycosylated with endoglycosidase F (EF), and control nonreceptor-bearing membranes from CHO cells were exposed to the same labeling procedure. The secretin receptor affinity-labeled with each probe migrated at approximate M r ϭ 70,000, shifting to approximate M r ϭ 42,000 after deglycosylation (A). No radioactive bands were observed in affinitylabeled nonreceptor bearing membranes. Shown in B are the densitometric analyses of receptor labeling in the presence of increasing concentrations of competing secretin in three similar independent experiments (means Ϯ S.E.).
(M r ϭ 8,500). Similarly, CNBr cleavage of the I334M receptor labeled with the Bpa Ϫ2 or Bpa 1 probe yielded a fragment migrating at approximate M r ϭ 4,500, distinct in size from the fragment resulting from cleavage of the labeled wild type or A175M receptor constructs (M r ϭ 8,500) (Fig. 5) . These data suggest that the sites of labeling for all three probes were within the fragment spanning ICL3, TM6 and the beginning of ECL3 of the receptor (Arg 300 -Met 344 ), but were at distinct sites within this fragment.
The fragments resulting from CNBr cleavage of the wild type receptor labeled with either Bpa Ϫ1 or Bpa Ϫ2 probe were also subjected to Edman degradation sequencing after extensive purification, as described under "Experimental Procedures." This resulted in the identification of the Arg-Lys-LeuArg-Thr-Gln-Glu-Thr-Arg-Gly-Ser-Glu in cycles 1-12. This sequence exits only in the rat secretin receptor and corresponds with the first 12 residues of the CNBr fragment spanning ICL3 and TM6 (Arg 300 -Met 344 ). This provided definitive identification of the fragment Arg 300 -Met 344 as the domain of labeling.
As also shown in Fig. 4B , CNBr cleavage of the I334M receptor mutant labeled with the Bpa Ϫ2 or Bpa 1 probe yielded a fragment migrating faster than that coming from cleavage of the same receptor mutant labeled with the Bpa Ϫ1 probe. Given the mass of the probes (see above), the CNBr fragment labeled with the Bpa Ϫ1 probe migrating at approximate M r ϭ 7,500 most likely represents the amino-terminal segment Arg 300 -Ile 334 , whereas the CNBr fragment labeled with the Bpa Ϫ2 or Bpa 1 probes which was migrating at approximate M r ϭ 4,500 most likely represents the carboxyl-terminal segment Val 335 -Met 344 . This was confirmed by endoproteinase Lys-C cleavage of the CNBr fragments from the labeled I334M mutant receptor (Fig. 4D) and by CNBr cleavage of the I334M/M344I dual receptor mutant labeled by each probe (see below and Fig. 6 ). As shown in Fig. 4D , further Lys-C cleavage of the CNBr fragment from the I334M construct labeled with the Bpa Ϫ1 probe resulted in a fragment shifting from approximate M r ϭ 7,500 to 4,500, suggesting that the site of labeling of the Bpa Ϫ1 probe was within the larger amino-terminal half of the CNBr fragment, within the segment Arg 300 -Ile 334 . However, the M r ϭ 4,500 CNBr fragment resulting from cleavage of the same mutant receptor labeled with the Bpa Ϫ2 or Bpa 1 probe did not shift after further Lys-C cleavage, indicating that the smaller carboxyl-terminal segment (Val 335 -Met 344 ) was the domain of labeling for both the Bpa Ϫ2 and Bpa 1 probes. To narrow further the domain of labeling for the Bpa Ϫ1 probe, two additional receptor constructs were generated to replace either Leu 324 or Ile 331 with Met (L324M and I331M). Both constructs bound normally and had cAMP responses similar to secretin (full efficacy) when transiently expressed in COS cells (Table I) . However, secretin was less potent in stimulating cAMP responses in both of these constructs relative to the wild type receptor (Table I ). This likely reflects the impor- tance of the TM6 domain in achieving the active conformation of this receptor. Both constructs were efficiently affinity labeled by the Bpa Ϫ1 probe, with the labeled band being competed off by 1 M secretin (Fig. 5A) . Like the wild type receptor, both constructs labeled with the Bpa Ϫ1 probe migrated at approximate M r ϭ 70,000, which shifted to approximate M r ϭ 42,000 after deglycosylation (Fig. 5A) . CNBr cleavage of the L324M receptor mutant labeled with the Bpa Ϫ1 probe resulted in a fragment migrating at approximate M r ϭ 5,000 which did not shift after further Lys-C cleavage, indicating that the site of labeling was within the segment Leu 325 -Met 344 (Fig. 5, B (Fig. 6B ). CNBr cleavage of the I334M/M344I mutant labeled with either A shows that each receptor construct was able to be labeled with all three probes saturably and specifically, with the labeled mutant receptors migrating at M r ϭ 70,000 similar to the wild type receptor. In B, like cleavage of the labeled wild type receptor, CNBr cleavage of the A175M mutant labeled with the Bpa Ϫ1 probe yielded a band migrating at approximate M r ϭ 8,500. This band shifted to approximate M r ϭ 7,500 in the I334M receptor mutant labeled with the Bpa Ϫ1 probe, confirming the fragment between receptor residues Arg 300 and Met 344 as being the domain labeled with the Bpa Ϫ1 probe (C). Because this M r ϭ 7,500 band was cleavable by endoproteinase Lys-C, which yielded a band migrating at M r ϭ 4,500, the site of labeling by the Bpa Ϫ1 probe was within the larger amino-terminal segment Arg the Bpa Ϫ2 or Bpa 1 probe also resulted in bands migrating at M r ϭ 14,500, representing the fragment Val 335 -Ile 427 , distinct in migration from the M r ϭ 8,500 CNBr fragment resulting from cleavage of the labeled wild type receptor (Fig. 6B) . Radiochemical sequencing of the labeled fragment His 332 -Ile   427 identified Tyr 333 as the site of labeling by the Bpa Ϫ1 probe (Fig.  7A) . Phe 336 and Phe 338 were identified as the receptor residues labeled by the Bpa Ϫ2 (Fig. 7B ) and Bpa 1 (Fig. 7C ) probes, respectively, by radiochemical sequencing of the labeled fragment Val 335 -Ile 427 . In summary, the sites of labeling with all three amino-terminal probes were demonstrated to be within the same region, at the top of TM6 of the secretin receptor, a distinct domain from that labeled with all secretin probes reported previously (8 -13). The site of labeling with the Bpa Ϫ1 probe was specifically localized to its receptor residue Tyr 333 , whereas the Bpa
Ϫ2
and Bpa 1 labeled the receptor residues Phe 336 and Phe 338 , respectively.
Molecular Modeling-In our previous modeling exercises (13), we have built a three-dimensional model of the secretin receptor and docked the secretin peptide based on the previous published photoaffinity cross-linking data (8 -13) . In that model, the amino terminus of the secretin peptide was observed near the transmembrane domain, fully consistent with current experimental work. In this report, the peptide was redocked into its binding site in the receptor model based on all available photoaffinity cross-linking data. The final complex satisfied all original crosslinking constraints as well as the new photoaffinity labeling data reported here quite well (Fig. 8) . This is most encouraging, because these cross-links involve receptor residue positions located in both amino-terminal region and TM6.
In the refined model, the bound peptide hormone is posi- . This identification was confirmed further by CNBr cleavage of the I331M/M344I secretin receptor mutant labeled with the Bpa Ϫ1 probe (see Fig. 6 ).
tioned with most residues close to the receptor amino-terminal region. The first five amino-terminal residues of the hormone are positioned quite close to the receptor extracellular loops, with His 1 near the top of the TM6 helix. This is consistent with both current photoaffinity labeling data and previous mutagenesis studies that suggested that Asp 3 of the secretin hormone may be directly involved in an interaction with the first extracellular loop (39) .
It should be noted, in the current model, that the receptor residue Phe 338 was placed facing the lipid bilayer rather than the helix bundle interior. This is because the modeling of the transmembrane helical bundle was based strictly on the rhodopsin x-ray structure (PDB code: 1F88), a Class A G proteincoupled receptor (40) . However, the helix bundle topology and conformations for the Class B family of G protein-coupled receptors are likely rather different from the Class A family (41, 42) . Therefore, the helix bundle domain of the secretin receptor model reported here should be regarded as a rough approximation at this stage.
DISCUSSION
Photoaffinity labeling represents a powerful method for studying the interactions of ligands with G protein-coupled receptors, by establishing spatial approximations between distinct residues within ligand and receptor. We previously developed and used six agonist analogs of secretin which incorporated photolabile residues into divergent regions of the ligand, in the amino-terminal half (in position 6), in the midregion (positions 12 and 14) , in the carboxyl-terminal half (in position 18 and 22) , and in the carboxyl terminus (position 26) of secretin (8 -11) . Each of these probes labeled residues within the first 40 residues of the amino-terminal domain of the secretin receptor. Recently, we also showed that another probe with the photolabile residue incorporated into the midregion of the peptide, in position 13, also labeled an amino-terminal residue in the secretin receptor (12) . However, this residue (Val 103 ) was close to the first transmembrane segment, rather than at the distal end of this domain (12) . Receptor mutagenesis studies have confirmed the importance of the amino-terminal domain of this receptor but, at the same time, supported a complementary role for extracellular loop domains. In an attempt to determine whether secretin might be directly interacting with such regions of the receptor body, as well as the amino terminus, we sought to extend our previous photoaffinity labeling studies.
In this work, we focused on the amino-terminal end of secretin, a region not previously directly analyzed by photoaffinity labeling. However, incorporation of a photolabile residue in the position of the first residue of secretin posed a challenge. The His residue in this position has been shown to be critical for binding and biological activity in structure-activity studies (16) . We therefore developed a series of three amino-terminal probes with a photolabile Bpa incorporated in position 1 (Bpa 1 probe), Ϫ1 (Bpa Ϫ1 probe), and Ϫ2 (Bpa Ϫ2 probe). The Bpa
Ϫ1
and Bpa Ϫ2 probes were prepared to avoid replacing His 1 and thereby attempt to minimize their negative functional impact. Although we have shown that all three probes were full agonists and bound to the secretin receptor specifically and saturably, incorporation of a photolabile Bpa in positions Ϫ2 and Ϫ1 indeed had less negative impact on both binding affinity and biological activity of the probes, than direct incorporation of Bpa to replace His 1 . Nevertheless, all three analogs were able to label the secretin receptor covalently, efficiently and specifically.
These probes offered a unique challenge for the identification of a specific residue that was covalently labeled. This relates to the fact that Edman degradation sequencing involves sequential cleavage of residues from the amino-terminal end of a peptide. Because that is the position of the photolabile Bpa in each of these probes, the site of covalent attachment would be released in the first cycle of such sequencing for each of these probes. To prevent this, we had to develop a strategy that would selectively prevent the cleavage of the probes, modifying the approach we had used so effectively in previous studies (9 -12, 24, 25). One possible solution was to block the amino terminus of the probes prior to receptor binding, but there was concern that this might also modify their interaction with the receptor. Therefore, we developed a strategy to block the amino groups chemically both within the probe and the labeled receptor after photoaffinity labeling, but prior to proteolytic cleavage to release a receptor fragment that would be amenable to sequencing. In this way, the photolabile amino-terminal probes bound to the receptor normally prior to photolysis. After acetylation, the free amino groups of the photolabile ligand and the secretin receptor were both blocked, but the labeled receptor fragment again became amenable to Edman degradation sequencing after CNBr cleavage. Because the probes had no methionine residues, they remained blocked after CNBr treatment. Using this approach, we were able to identify the specific receptor residues covalently labeled by each of the three aminoterminal photolabile probes.
Of note, all three probes consistently labeled a single and consistent receptor domain. The Bpa 1 probe labeled residue Phe 338 , whereas the Bpa Ϫ1 and Bpa Ϫ2 probes labeled receptor residues Tyr 333 and Phe 336 , respectively. Each of these residues is predicted to reside high in the sixth transmembrane segment. This is the first secretin receptor domain covalently labeled in such an experiment which is distinct from the amino terminus, which had been labeled by each of the previously studied probes (8 -13) .
Mutagenesis studies have suggested an important role for the top of the sixth transmembrane segment within the PTH receptor, another Class B G protein-coupled receptor (43, 44) . This domain has also been shown to be important for Class A receptors, such as the m5 muscarinic receptor (45) and the ␣-factor pheromone receptor (46) . The top of the sixth transmembrane segment was also labeled directly in a series of analogous photoaffinity labeling studies of the PTH receptor. Of interest, photoaffinity labeling probes with a Bpa at the amino terminus of PTH, either in position 1 (14) or in position 2 (15) , labeled Met 425 , near the top of the sixth transmembrane segment of the PTH-1 receptor. Similar results have been obtained with the PTH-2 receptor (47). Furthermore, an antagonist probe with a Bpa in position 2 of the amino terminus of PTH-related peptide, labeled Met 425 within the same region of the PTH-1 receptor (15) .
These data have supported the proposed model for binding of PTH to its receptors, where the carboxyl terminus of the natural peptide ligand interacts with the amino-terminal tail of the receptor, whereas the peptide amino terminus inserts itself into the membrane in the confluence of helices (48) . Such a tethering between two distinct domains of a receptor could provide a mechanism to exert tension and thereby change the conformation of the body of the receptor. This, in turn, could be transmitted to the cytosolic face of the receptor where the G protein interaction occurs.
The current report suggests that a similar theme might be relevant to the secretin receptor, another member of the same family of receptors. Our previous observations with probes incorporating photolabile sites of covalent attachment in positions 12, 13, 14, 18, 22, and 26 of secretin ((BzBz)Lys 12 , Bpa 13 , (BzBz)Lys 14 , (BzBz)Lys 18 , Bpa 22 and Bpa 26 probes (8, 10 -13)) established the approximation between the peptide carboxyl terminus and the amino-terminal domain of the receptor. The current observations establish the approximation between the peptide amino terminus and the body of the receptor. However, our previous observation with the Bpa 6 probe may suggest a difference (9) . That probe also labeled the receptor amino terminus. Only a detailed molecular model of the ligand-receptor complex will resolve the similarities and differences between these two extensively studied receptors. Previous modeling exercises enabled us to build the first secretin-receptor complex model, which was subsequently refined by photoaffinity cross-linking data reported here. In the current model, only the first four or five secretin amino-terminal residues were positioned close to the receptor extracellular loops, with His 1 positioned at the top of transmembrane helix six. Hence, the refined model supports the mechanism that the binding of secretin ligand tethers the two domains of the receptor, the amino terminus and transmembrane domain, and suggests that the signal transduction mechanism may well be similar to that proposed for the PTH receptors.
In summary, we have now developed three new amino-terminal photolabile secretin probes and have applied them to study residue-residue approximations as docked at the secretin receptor. Each probe covalently labeled a residue near the top of the TM6 of the secretin receptor, a region that is distinct from that labeled by probes utilized previously (8 -13) . Thus, we have provided additional critical spatial constraints that are useful for the modeling of the agonist-bound secretin receptor. These new insights support a mechanism for receptor activation similar to that proposed for the PTH receptor, where the agonist peptide spans two distinct domains of the receptor, providing a mechanism to exert tension and change conformation. This may be a common theme for the Class B G proteincoupled receptors.
